Loading
CAPOX pairs the oral fluoropyrimidine capecitabine with intravenous oxaliplatin as a pill-based alternative to FOLFOX. For low-risk stage III colon cancer three months after surgery works as well as six and halves nerve damage; it is also standard in gastric cancer, with hand-foot syndrome as its price.
IDEA collaboration (2018): 3 months of CAPOX is non-inferior to 6 for low-risk stage III (T1-3 N1) colon cancer, halving neuropathy. Standard perioperative and first-line option in gastric cancer (with nivolumab in CheckMate 649; with zolbetuximab in GLOW). Hand-foot syndrome from capecitabine replaces some 5-FU toxicity.
Capecitabine is an oral prodrug of 5-FU activated preferentially in tumour; oxaliplatin crosslinks DNA.
1.CAPOX (capecitabine, oxaliplatin) slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Adverse event |
|---|
| Hand-foot syndrome |
| Peripheral neuropathy |
| Diarrhoea |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
A UK-led trial that moved part of colon cancer chemotherapy in front of the operation, and showed that tumour regression grade after six weeks predicts recurrence, which is the basis for using the response itself to choose what follows.
Organ preservation became a plan rather than an accident: consolidation chemotherapy after chemoradiotherapy gives the best chance of keeping the rectum, and salvage surgery after regrowth does not appear to cost survival.
The first total neoadjuvant therapy trial to change practice in high-risk rectal cancer, and the schedule that makes organ preservation possible by giving the tumour months rather than weeks to respond.
The European rulebook for what happens after a colon cancer operation, and the reason a patient with a T3 N1 tumour is now offered three months of chemotherapy rather than six.
The standard-of-care rows on the appendiceal pages, particularly who is referred for cytoreductive surgery and who receives chemotherapy, follow this consensus and the NCCN appendiceal section.
The largest de-escalation exercise in adjuvant oncology, and the reason a patient with a T3 N1 colon cancer is now offered four cycles of CAPOX rather than twelve of FOLFOX, with a fraction of the neuropathy.
Fluoropyrimidine plus oxaliplatin is the first-line chemotherapy for advanced small bowel adenocarcinoma and the regimen tested after surgery in BALLAD.
Query for this drug: (TITLE:"CAPOX" OR ABSTRACT:"CAPOX" OR TITLE:"capecitabine, oxaliplatin" OR ABSTRACT:"capecitabine, oxaliplatin" OR TITLE:"XELOX" OR ABSTRACT:"XELOX") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAPOX (capecitabine, oxaliplatin), not a curated reading list.
Shares Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer, BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours, A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors, HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer.
Shares HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer, Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma, Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer, A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer.
Shares BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours, A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer, Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab, Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV.
Shares BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours, A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients, Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab, Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV.
Shares Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer, Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer, A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC), Rachel Kerr.
Shares A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients, A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer, CAIRO3, Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV.
Shares Micropapillary adenocarcinoma of the colon and rectum, Adenoma-like adenocarcinoma of the colon and rectum, Familial adenomatous polyposis-associated colorectal cancer, Goblet cell adenocarcinoma of the appendix.
Shares Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer, CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial), Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Co, Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk.